Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity

The successful application of a non-oncogenic virus, Newcastle disease virus (NDV), which can be used to modify a highly metastatic tumor to become more immunogenic is reported. Such NDV modified tumor cells were found to be effective as tumor vaccine for anti-metastatic therapy in combination with...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental metastasis 1987-04, Vol.5 (2), p.147-156
Main Authors: Schirrmacher, V, Heicappell, R
Format: Article
Language:English
Subjects:
Animals
Cell Transformation, Viral
Immunotherapy
Lymphoma - secondary
Mice
Mice, Inbred DBA
Neoplasm Metastasis - prevention & control
Newcastle disease virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The successful application of a non-oncogenic virus, Newcastle disease virus (NDV), which can be used to modify a highly metastatic tumor to become more immunogenic is reported. Such NDV modified tumor cells were found to be effective as tumor vaccine for anti-metastatic therapy in combination with surgical removal of the primary tumor. The protection in the animals seen after this treatment is paralleled by an establishment of specific systemic anti-tumor immunity. This protective immunity depended on recognition of a distinct tumor antigen. The therapy protocol also worked in animals bearing the plastic adhesive variant ESb-MP. It did not work, however, when using an immune escape variant not expressing a specific tumor antigen.
ISSN:0262-0898
1573-7276
DOI:10.1007/BF00058060